STAT42%
Nabla’s new CEO on plan to gain market share in a competitive AI scribe environment 74%
By Brittany Trang82%
7/21/2026, 12:00:00 PM
Topics: Artificial Intelligence, Health Tech
BS Summary: This article contains 13 faulty reasoning types, including Ambiguity (Equivocation), Appeal to Authority, and Optimism Bias, with Overconfidence Bias as the most egregious example at 26% saturation with 46 hits. Analysis detected 355 faulty-reasoning hits from 177 analyzed words, generating a BS Score of 66.7% and a BS Rank of 74% (5,333 of 20,452 articles). This article is worse (more manipulative) than 73.90% of the article peer group.
Nabla, the Paris-based maker of ambient scribes used to automate clinical documentation, says it’s playing the long game.
On Tuesday the company announced a new leader and reiterated its commitment to fundamentally new AI technology it believes can help it beat the competition.
The company, which last raised a $70 million Series B last summer, announced a new CEO, Brian Manning, who has served as chief revenue officer at care coordination software company PatientPing and its acquirer, Bamboo Health, before taking over as Bamboo’s president.
The shift “marks the next phase of Nabla’s go-to-market strategy,” the company wrote in a press release.
“We really haven’t built our brand in the United States.
We really haven’t accelerated our go-to-market in line with what others are doing.
And as we look towards 2027, that’s something we’re absolutely going to be doing,” Manning said in an interview with STAT.
Chief operating officer Delphine Groll said that 100% of the company’s revenue is from the U.S.
Speakers
3speakers68%attributed speech57writer words
Voice mapSelect a segment to jump to its words
Selected voice
100%flagged-word coverageNabla
60 attributed words50% of attributed speech74% writer coverage
Attribution is sentence-level. Pattern percentages are calculated only from words assigned to that voice.
Loading…
Loading…
Loading…
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.